A single arm, open-label, phase 2 study to assess the efficacy and safety of lucitanib given orally as a single agent to patients with advanced/metastatic lung cancer and FGF, VEGF, or PDGF related genetic alterations
Latest Information Update: 22 Jul 2022
Price :
$35 *
At a glance
- Drugs Lucitanib (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Clovis Oncology [CEASED]; Clovis Oncology Italy; EOS S.p.A.
- 18 Jul 2022 Results of a Pop PK pooled analysis from five phase 1 and 2 clinical studies: NCT01283945, NCT02053636, ISRCTN23201971, NCT02202746 and NCT02109016 published in the European Journal of Drug Metabolism and Pharmacokinetics
- 12 Sep 2018 Status changed to discontinued.
- 27 Jul 2016 Planned End Date changed from 1 Aug 2016 to 1 Oct 2016.